BBHC
CLBT icon

Brown Brothers Harriman & Co’s Cellebrite CLBT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,020
Closed -$7.34K – 1231
2023
Q2 		$7.34K Buy
+1,020
New +$5.95K ﹤0.01% 1007

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
MCM
Makena Capital Management Menlo Park, California $952M AUM 13.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $903M AUM 113.12% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Brown Brothers Harriman & Co's CLBT Position: Q3 2023 in Review

Brown Brothers Harriman & Co sold out of Cellebrite (CLBT) in Q3 2023, closing a stake of 1,020 shares — an estimated $7.34K sold.

Brown Brothers Harriman & Co first reported a position in CLBT in Q2 2023 and held it in 1 quarter. The position peaked at $7.34K in Q2 2023. 94 funds tracked by Wall St. Rank hold CLBT as of Q3 2023.

  • Brown Brothers Harriman & Co reported no remaining Cellebrite position as of Q3 2023 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 1,020 Cellebrite shares in Q3 2023, an estimated $7.34K.
  • Brown Brothers Harriman & Co first reported a position in Cellebrite in Q2 2023 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Cellebrite position peaked at $7.34K in Q2 2023.
  • 94 funds tracked by Wall St. Rank held Cellebrite as of Q3 2023.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2023, filed 13 Nov 2023.